spiperone has been researched along with Parkinson Disease, Secondary in 17 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with bromocriptine was very effective and five months after the poisoning, MR and (11)C-NMSP/PET images showed improvement, concomitantly with the disappearance of the neuropsychiatric symptoms." | 5.30 | Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. ( Haida, M; Kozuma, R; Shinohara, Y; Takagi, S; Takahashi, W; Yoshii, F, 1998) |
| "Treatment with bromocriptine was very effective and five months after the poisoning, MR and (11)C-NMSP/PET images showed improvement, concomitantly with the disappearance of the neuropsychiatric symptoms." | 1.30 | Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. ( Haida, M; Kozuma, R; Shinohara, Y; Takagi, S; Takahashi, W; Yoshii, F, 1998) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (47.06) | 18.7374 |
| 1990's | 9 (52.94) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gnanalingham, KK | 2 |
| Erol, DD | 1 |
| Hunter, AJ | 2 |
| Smith, LA | 2 |
| Jenner, P | 2 |
| Marsden, CD | 2 |
| Curran, EJ | 1 |
| Albin, RL | 1 |
| Becker, JB | 1 |
| Alexander, GM | 1 |
| Schwartzman, RJ | 1 |
| Grothusen, JR | 1 |
| Brainard, L | 1 |
| Gordon, SW | 1 |
| Yoshii, F | 1 |
| Kozuma, R | 1 |
| Takahashi, W | 1 |
| Haida, M | 1 |
| Takagi, S | 1 |
| Shinohara, Y | 1 |
| Borbely, K | 1 |
| Brooks, RA | 1 |
| Wong, DF | 1 |
| Burns, RS | 1 |
| Cumming, P | 1 |
| Gjedde, A | 1 |
| Di Chiro, G | 1 |
| Cadet, JL | 1 |
| Zhu, SM | 1 |
| Lisovoski, F | 1 |
| Haby, C | 1 |
| Borrelli, E | 1 |
| Schleef, C | 1 |
| Revel, MO | 1 |
| Hindelang, C | 1 |
| Zwiller, J | 1 |
| Rouillard, C | 1 |
| Bédard, PJ | 3 |
| Di Paolo, T | 3 |
| Camps, M | 1 |
| Ambrosio, S | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Joyce, JN | 1 |
| Marshall, JF | 1 |
| Bankiewicz, KS | 1 |
| Kopin, IJ | 1 |
| Jacobowitz, DM | 1 |
| Ruberg, M | 1 |
| Javoy-Agid, F | 1 |
| Hirsch, E | 1 |
| Scatton, B | 1 |
| LHeureux, R | 1 |
| Hauw, JJ | 1 |
| Duyckaerts, C | 1 |
| Gray, F | 1 |
| Morel-Maroger, A | 1 |
| Rascol, A | 1 |
| Crossman, AR | 1 |
| Clarke, CE | 1 |
| Boyce, S | 1 |
| Robertson, RG | 1 |
| Sambrook, MA | 1 |
| Falardeau, P | 2 |
| Bouchard, S | 1 |
| Boucher, R | 2 |
| Beresford, IJ | 1 |
| Davenport, AP | 1 |
| Sirinathsinghji, DJ | 1 |
| Hall, MD | 1 |
| Hill, RG | 1 |
| Hughes, J | 1 |
| Hantraye, P | 1 |
| Loc'h, C | 1 |
| Tacke, U | 1 |
| Riche, D | 1 |
| Stulzaft, O | 1 |
| Doudet, D | 1 |
| Guibert, B | 1 |
| Naquet, R | 1 |
| Mazière, B | 1 |
| Mazière, M | 1 |
1 review available for spiperone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levo | 1987 |
16 other studies available for spiperone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benza | 1995 |
Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Benzazepines; Cerebral Ventricles; Corpus Striat | 1993 |
Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Levodop | 1993 |
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Callith | 1993 |
Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning.
Topics: Basal Ganglia; Bromocriptine; Carbon Monoxide Poisoning; Carbon Radioisotopes; Caudate Nucleus; Cere | 1998 |
NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Antiparkinson Agents; Binding Sites; Cerebellum | 1999 |
The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Biomarkers; Corpus Striatum; Immunohistochemistr | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; | 1992 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Carotid Arteries; Corpus Str | 1986 |
Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
Topics: Aged; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltransferase; Corpus Striatum; Dopamine; Fema | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autoradiography; Benzazepines; Corpus Striatum; Functional Lat | 1988 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; | 1986 |
"In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromine; Corpus Striatum; Disease Models, Ani | 1986 |